Panakes Partners

Panakes Partners, established in 2015, is a Milan-based venture capital firm focused on early-stage investments in the life sciences sector. The company, founded by Fabrizio Landi, Alessio Beverina, and Diana Saraceni, invests in ambitious startups and teams across Europe and Israel, aiming to support revolutionary technologies and products that improve global health. With 250 million under management, Panakes Partners seeks to foster innovation and growth in the life sciences and healthcare industries.

Lorenzo Giordano

CFO

Giacomo Piccinini

Associate

Alessio Piuma

Investment Manager

Diana Saraceni

General Partner

Marco Sardina Ph.D

Scientific Partner

Rob Woodman

Partner

Rob Woodman

Partner

Alessio Piuma

Investment Manager

Past deals in Italy

TENSIVE

Series A in 2025
TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

BetaGlue Technologies

Seed Round in 2022
BetaGlue Technologies SpA specializes in the development and manufacture of medical devices designed for loco-regional radiation therapy targeting unresectable solid tumors. The company's innovative product utilizes a proprietary beta-emitting bio-compatible matrix, facilitating the controlled administration of radionuclides directly into tumor masses. This technology not only aims to enhance treatment efficacy but also plays a crucial role in preventing complications that may arise from procedures such as lung and liver biopsies and other localized treatments. Headquartered in Milan, Italy, BetaGlue Technologies is focused on advancing therapeutic options in the field of oncology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.